CHEK2 and breast cancer: In fact, we already performed the splicing assays of 706 variants of the BC susceptibility genes BRCA1, BRCA2, CHEK2, RAD51C, RAD51D, PALB2, and ATM, of which 431 (61%) induced splicing disruptions and 243 (34%) were classified as pathogenic or likely pathogenic.